Andrew G. Stead
- Oncology top 5%
- Pulmonary and Respiratory Medicine top 5%
- Molecular Biology
- Cancer Research top 5%
- Radiology, Nuclear Medicine and Imaging top 5%
- Co-authors
- Kevin M. KochDeborah A. SmithNeil L. SpectorAfshin DowlatiHoward A. BurrisHerbert I. HurwitzBeth OvermoyerBert H. O’Neil
- Topics
- HER2/EGFR in Cancer Research (12 papers)Colorectal Cancer Treatments and Studies (10 papers)Lung Cancer Treatments and Mutations (9 papers)
- Partner nations
- United StatesUnited KingdomAustria
In The Last Decade
Andrew G. Stead
53 papers receiving 1.9k citations
Hit Papers
Peers
Comparison fields: 5 of 130
- Oncology 954
- Pulmonary and Respiratory Medicine 501
- Molecular Biology 414
- Cancer Research 354
- Radiology, Nuclear Medicine and Imaging 275
Countries citing papers authored by Andrew G. Stead
This map shows the geographic impact of Andrew G. Stead's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew G. Stead with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew G. Stead more than expected).
Fields of papers citing papers by Andrew G. Stead
This network shows the impact of papers produced by Andrew G. Stead. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew G. Stead. The network helps show where Andrew G. Stead may publish in the future.
Co-authorship network of co-authors of Andrew G. Stead
This figure shows the co-authorship network connecting the top 25 collaborators of Andrew G. Stead. A scholar is included among the top collaborators of Andrew G. Stead based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew G. Stead. Andrew G. Stead is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomasbreakdown → | 503 |
| 2 | 290 | |
| 3 | 98 | |
| 4 | 4 | |
| 5 | 13 | |
| 6 | 3 | |
| 7 | 4 | |
| 8 | 22 | |
| 9 | 7 | |
| 10 | 101 | |
| 11 | 17 | |
| 12 | 5 | |
| 13 | 5 | |
| 14 | 19 | |
| 15 | 9 | |
| 16 | 40 | |
| 17 | Tumorigenesis and genotoxicity of ethyl carbamate and vinyl carbamate in rodent cells. | 23 |
| 18 | 6 | |
| 19 | 0 | |
| 20 | 4 |
About Andrew G. Stead
Andrew G. Stead is a scholar working on Chemical Health and Safety, Health, Toxicology and Mutagenesis and Behavioral Neuroscience, having authored 54 papers that have together received 2.0k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (12 papers), Colorectal Cancer Treatments and Studies (10 papers) and Lung Cancer Treatments and Mutations (9 papers). The work is most often cited by research in Oncology (954 citations), Chemical Health and Safety (17 citations) and Genetics (258 citations). Andrew G. Stead has collaborated with scholars based in United States, United Kingdom and Austria. Frequent co-authors include Kevin M. Koch, Deborah A. Smith, Neil L. Spector, Afshin Dowlati, Howard A. Burris, Herbert I. Hurwitz, Beth Overmoyer, Bert H. O’Neil, Matthew J. Ellis and Kimberly Blackwell. Their work appears in journals such as Journal of Clinical Oncology, Journal of the American Statistical Association and Stroke.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.